Language
English
Publication Date
10-16-2025
Journal
Nature Communications
DOI
10.1038/s41467-025-64236-x
PMID
41102182
PMCID
PMC12532822
PubMedCentral® Posted Date
10-16-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Clonal hematopoiesis (CH) is defined by the expansion of a lineage of genetically identical cells in blood. Genetic lesions that confer a fitness advantage, such as leukemogenic point mutations or mosaic chromosomal alterations (mCAs), are frequent mediators of CH. However, recent analyses of both single cell-derived colonies of hematopoietic cells and population sequencing cohorts have revealed CH frequently occurs in the absence of known driver genetic lesions. To characterize CH without known driver genetic lesions, we use 51,399 deeply sequenced whole genomes from the NHLBI TOPMed sequencing initiative to perform simultaneous germline and somatic mutation analyses among individuals without leukemogenic point mutations (LPM), which we term CH-LPMneg. We quantify CH by estimating the total mutation burden. Because estimating somatic mutation burden without a paired-tissue sample is challenging, we develop a novel statistical method, the Genomic and Epigenomic informed Mutation (GEM) rate, that uses external genomic and epigenomic data sources to distinguish artifactual signals from true somatic mutations. We perform a genome-wide association study of GEM to discover the germline determinants of CH-LPMneg. We identify seven genes associated with CH-LPMneg (TCL1A, TERT, SMC4, NRIP1, PRDM16, MSRA, SCARB1).Functional analyses of SMC4 and NRIP1 implicated altered hematopoietic stem cell self-renewal and proliferation as the primary mediator of mutation burden in blood. We then perform comprehensive multi-tissue transcriptomic analyses, finding that the expression levels of 404 genes are associated with GEM. Finally, we perform phenotypic association meta-analyses across four cohorts, finding that GEM is associated with increased white blood cell count, but is not significantly associated with incident stroke or coronary disease events. Overall, we develop GEM for quantifying mutation burden from WGS and use GEM to discover the genetic, genomic, and phenotypic correlates of CH-LPMneg.
Keywords
Humans, Point Mutation, Genome-Wide Association Study, Clonal Hematopoiesis, Genomics, Germ-Line Mutation, Genetics, Cancer epidemiology, Computational biology and bioinformatics
Published Open-Access
yes
Recommended Citation
Weinstock, Joshua S; Chaudhry, Sharjeel A; Ioannou, Maria; et al., "Genetic Determinants and Genomic Consequences of Non-Leukemogenic Somatic Point Mutations" (2025). Faculty and Staff Publications. 4254.
https://digitalcommons.library.tmc.edu/baylor_docs/4254